Advertisement

European Journal of Epidemiology

, Volume 34, Issue 11, pp 1103–1105 | Cite as

Interaction between co-morbidities and cancer survival

  • Andrew G. RenehanEmail author
  • Nasra N. Alam
  • Matthew Sperrin
CORRESPONDENCE
  • 163 Downloads

Comorbidities, for example, cardiovascular disease (CVD), diabetes, and chronic kidney disease, commonly co-occur in patients with cancer. For example, in the EPIC-Heidelberg Study [1], the prevalence of multi-morbidity (≥ 2 concurrent chronic diseases) was present in up to two-thirds of individuals aged 50 to 75 years. There is a large volume of evidence that, not unsurprisingly, the presence of a co-morbidity prognosticates for worse survival. In turn, this invites cancer health professionals to explore opportunities to intervene to lessen the risks of comorbidity-associated mortalities among cancer survivors. These patients have regular healthcare contact and are often well-motivated, with opportunities to exploit teachable moments. By example, the American Cancer Society Colorectal Cancer (CRC) Survivorship Care Guidelines [2] recommend that patients are informed of the adverse effects of obesity on CVD risk.

An alternative, but infrequently asked question is whether the presence...

Notes

Authors contributions

AGR and MS conceived the project. AGR and MS are the joint principal investigators for the study. NNA is the clinical research fellow and is responsible for management of the project. All authors critically revised the manuscript. All authors confirm that they meet ICMJE criteria for authorship.

Funding

This work was supported by CRUK via the funding to Cancer Research UK Manchester Centre: [C147/A18083] and [C147/A25254]. AGR is supported by the Manchester NIHR Biomedical Research Centre [IS-BRC-1215-20007].

Compliance with ethical standards

Conflict of interest

AGR has received lecture honoraria from Merck Serona and Janssen-Cilag, and independent research funding and lecture honoraria from Novo Nordisk and Sanofi Pasteur MSD. All other authors declare no competing interests.

References

  1. 1.
    Nagel G, Peter R, Braig S, Hermann S, Rohrmann S, Linseisen J. The impact of education on risk factors and the occurrence of multimorbidity in the EPIC-Heidelberg cohort. BMC Public Health. 2008;8:384.  https://doi.org/10.1186/1471-2458-8-384.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    El-Shami K, Oeffinger KC, Erb NL, et al. American cancer society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015;65(6):428–55.  https://doi.org/10.3322/caac.21286.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Baade PD, Fritschi L, Eakin EG. Non-cancer mortality among people diagnosed with cancer (Australia). Cancer Causes Control. 2006;17(3):287–97.  https://doi.org/10.1007/s10552-005-0530-0.CrossRefPubMedGoogle Scholar
  4. 4.
    van Erning FN, van Steenbergen LN, Lemmens V, et al. Conditional survival for long-term colorectal cancer survivors in the Netherlands: who do best? Eur J Cancer. 2014;50(10):1731–9.  https://doi.org/10.1016/j.ejca.2014.04.009.CrossRefPubMedGoogle Scholar
  5. 5.
    Badrick E, Sperrin M, Buchan IE, Renehan AG. Obesity paradox and mortality in adults with and without incident type 2 diabetes: a matched population-level cohort study. BMJ Open Diabetes Res Care. 2017;5(1):e000369.  https://doi.org/10.1136/bmjdrc-2016-000369.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Division of Cancer Sciences, Manchester Academic Health Science Centre, School of Medical Sciences, Faculty of Biology, Medicine and HealthUniversity of ManchesterManchesterUK
  2. 2.Manchester Cancer Research CentreNational Institute for Health Research (NIHR) Manchester Biomedical Research CentreManchesterUK
  3. 3.Health eResearch Centre, School of Health Sciences, Faculty of Biology, Medicine and HealthUniversity of ManchesterManchesterUK

Personalised recommendations